Project Grant R01MH139651
- Federal Grant Award Summary The National Institute of Mental Health (NIMH) awarded $394,200 to the Research Foundation For Mental Hygiene, Inc. (RFMH) under the Mental Health Research Grants program (CFDA 93.242) beginning August 1, 2025, with a completion date of July 31, 2030. This project grant funds a five-year clinical research investigation examining the role of the anterior hippocampus in the pathogenesis of major depressive disorder (MDD). The research leverages functional magnetic...
- Federal Grant Award Summary The National Institute of Mental Health (NIMH) awarded The Feinstein Institutes for Medical Research a Project Grant of $519,558 under the Mental Health Research Grants program (CFDA 93.242), effective June 15, 2025 through April 30, 2030. The research project focuses on identifying and validating cerebellar-cortical circuitry biomarkers as predictive indicators of antipsychotic treatment response in first-episode psychosis patients. The primary deliverables...
- Federal Project Grant Award Summary New York University School of Medicine received a $815,251 project grant from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242), effective June 1, 2025, through March 31, 2030. The award funds a comprehensive evaluation of Medicaid Delivery System Reform Incentive Payment (DSRIP) programs and their impacts on healthcare utilization, care coordination, and health outcomes among Medicaid enrollees with...
- Federal Grant Award Summary The National Institute of Mental Health (NIMH) awarded a Project Grant of $778,548 to the Research Foundation For Mental Hygiene, Inc. (Nathan S Kline Institute for Psychiatric Research) on September 19, 2025, under the Mental Health Research Grants program (CFDA 93.242). This five-year research initiative, concluding July 31, 2030, investigates the neural mechanisms underlying social cognitive deficits in schizophrenia, with particular focus on the third visual...
- Federal Project Grant Award Summary The National Institute of Mental Health (NIMH) awarded the University of Rochester a $423,500 Project Grant under the Mental Health Research Grants program (CFDA 93.242) on May 5, 2025, with a completion date of May 4, 2027. This award supports research investigating visual perception and predictive processing dysfunction in schizophrenia and related psychiatric disorders. The research employs high-density electroencephalography (EEG) and innovative visual...
- Federal Grant Award Summary The Feinstein Institutes for Medical Research received a $1,659,568 Project Grant from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242), awarded June 2, 2025, with completion targeted for May 31, 2030. The award funds the ESPRITO EPINET project, which aims to expand a learning health system (LHS) framework for improving treatment outcomes in early first-episode psychosis (FEP) care. The project will enroll an...
- Federal Grant Award Summary The National Institute of Mental Health (NIMH) awarded The Johns Hopkins University a $804,690 Project Grant under the Mental Health Research Grants program (CFDA 93.242), effective June 12, 2025 through April 30, 2030. This research project investigates the relationship between N-acetyl-aspartyl-glutamate (NAAG), a peptide neurotransmitter, and memory deficits in schizophrenia patients in mid- to late-life. The primary deliverable involves measuring NAAG levels using...
- Federal Grant Award Summary New York University School of Medicine is conducting a clinical research project funded by the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242). The $871,225 project grant, awarded March 1, 2026, with a completion date of November 30, 2030, investigates psilocybin as a novel therapeutic intervention for residual anhedonia in patients currently taking selective serotonin reuptake inhibitors (SSRIs). The research...
- Federal Grant Award Summary New York University received a $710,563 Project Grant from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242), awarded on March 5, 2026, with a completion date of November 30, 2030. The award supports fundamental neuroscience research investigating the neural circuit mechanisms underlying dynamic learning rates in reinforcement learning. The research will determine how orbitofrontal cortex (OFC) projections...
- Federal Grant Award Summary Vanderbilt University received a $217,818 Project Grant from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242), awarded September 9, 2025, with completion targeted for September 8, 2027. The award funds research investigating metabotropic glutamate receptor (mGlu) signaling, specifically Group III mGlu receptors (mGlu4/7/8), as potential therapeutic targets for modulating glutamatergic synaptic transmission in...
The National Institute of Mental Health (NIMH) awarded $843,322 to the Research Foundation For Mental Hygiene, Inc. (RFMH) on March 5, 2026, under the Mental Health Research Grants program (CFDA 93.242) to conduct longitudinal positron emission tomography (PET) imaging research examining antipsychotic medication binding to the dopamine-3 receptor (D3R) in schizophrenia patients. The project, which extends through November 30, 2030, investigates the acute and subchronic effects of antipsychotic medications on D3R occupancy and upregulation, with the objective of elucidating the contribution of D3R binding to antipsychotic therapeutic response. The research will include comparative analysis of D2R-preferring and D3R-preferring antipsychotic medications to resolve discrepancies in existing literature regarding receptor binding patterns and homeostatic responses to chronic treatment. The deliverables from this project include scientific findings on the longitudinal neurobiological mechanisms underlying antipsychotic action, with particular focus on differentiating D3R binding profiles across medication types and dosing schedules. Results will advance understanding of how receptor occupancy correlates with clinical therapeutic outcomes, potentially informing more effective treatment strategies for schizophrenia and establishing methodological standards for in vivo neuroimaging studies of antipsychotic pharmacodynamics. Research will be conducted at the New York State Psychiatric Institute in New York, NY.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $843.3k | 3/5/26 |